Centene Corporation (CNC) valuation
Centene P/E ratio history
Centene trades at 22.7 times its earnings over the last twelve months and 12.6 times the earnings analysts expect over the next twelve. At its last 9 fiscal year ends its P/E ranged from 9.6 (year to Dec 2024) to 39.6 (year to Dec 2022), with a median of 20.0.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $41.15 | -$13.53 | n/m | 15.3 |
| Dec 31, 2024 | $60.58 | $6.31 | 9.6 | 8.6 |
| Dec 31, 2023 | $74.21 | $4.95 | 15.0 | 11.2 |
| Dec 31, 2022 | $82.01 | $2.07 | 39.6 | 13.3 |
| Dec 31, 2021 | $82.40 | $2.28 | 36.1 | 15.4 |
| Dec 31, 2020 | $60.03 | $3.12 | 19.2 | — |
| Dec 31, 2019 | $62.87 | $3.14 | 20.0 | — |
| Dec 31, 2018 | $57.65 | $2.33 | 24.7 | — |
| Dec 31, 2017 | $50.44 | $2.34 | 21.6 | — |
| Dec 31, 2016 | $28.25 | $1.58 | 17.8 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Centene valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| CenteneCNC | $33.8B | 22.7 | 12.6 | 0.2 |
| LabcorpLH | $29.6B | 29.7 | 18.6 | 2.1 |
| Quest DiagnosticsDGX | $27.8B | 25.1 | 21.3 | 2.4 |
| HumanaHUM | $49.8B | 39.1 | 31.6 | 0.3 |
| Veeva SystemsVEEV | $50.8B | 51.2 | 32.1 | 14.7 |
| Cardinal HealthCAH | $58.7B | 34.6 | — | 0.2 |
| CignaCI | $78.9B | 12.3 | 9.3 | 0.3 |
| SolventumSOLV | $14.1B | 9.9 | 11.3 | 1.7 |
| Elevance HealthELV | $91.2B | 17.8 | 14.0 | 0.5 |
| Peer median | 27.4 | 18.6 | 1.1 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: CNC financials · CNC returns
No forecast, no recommendation. This page describes Centene Corporation from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.